A venture capital firm based in Western Europe owns several funds and currently focuses on investments in Europe based diagnostics companies. The firm invests in Europe and North America, and typically allocates about €5 million equity to each portfolio company, generally over several tranches.
The firm invests in therapeutics and diagnostics to treat rare diseases. The firm is agnostic regarding technologies and indication areas, and typically invests early but is open to companies with assets ranging from preclinical development through Phase II.
The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply